Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis (OPERA-T Study)

NCT05238116 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
85
Enrollment
INDUSTRY
Sponsor class

Stopped The study was terminated by the Sponsor based on a sample size recalculation interim analysis which showed a numerically lower favorable response rate and a numerically higher mortality rate in the opelconazole arm compared to the control arm.

Conditions

Interventions

Sponsor

Pulmocide Ltd